Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of …
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
This week | ||
Is Definium Therapeutics, Inc. (DFTX) Stock a Biotech Opportunity After Positive DT120 Depression Trial Data? We recently compiled a list of the 7 Best Psychedelic Stocks to Buy According to Analysts. Definium Therapeutics, Inc. (NASDAQ:DFTX) is one of the best psychedelic stocks on our list. TheFly reported on June 30 that Canaccord reduced its price target on DFTX to $58 from $60 while reaffirming a Buy rating on the shares. The firm […] | ||
The Race to Commercialize the World’s Most Powerful Psychedelic An obscure psychedelic is drawing intense interest from the pharmaceutical industry. WSJ explores why companies are betting hundreds of millions of dollars on the therapeutic potential of a toad poison. | ||
Wall Street Analysts Think Definium Therapeutics, Inc. (DFTX) Could Surge 32.42%: Read This Before Placing a Bet The average of price targets set by Wall Street analysts indicates a potential upside of 32.4% in Definium Therapeutics, Inc. (DFTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. | ||
Older | ||